TADA-a machine learning tool for functional annotation-based prioritisation of pathogenic CNVs.

Clicks: 137
ID: 277466
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #19 of 24 articles by views in Genome biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Few methods have been developed to investigate copy number variants (CNVs) based on their predicted pathogenicity. We introduce TADA, a method to prioritise pathogenic CNVs through assisted manual filtering and automated classification, based on an extensive catalogue of functional annotation supported by rigourous enrichment analysis. We demonstrate that our classifiers are able to accurately predict pathogenic CNVs, outperforming current alternative methods, and produce a well-calibrated pathogenicity score. Our results suggest that functional annotation-based prioritisation of pathogenic CNVs is a promising approach to support clinical diagnostics and to further the understanding of mechanisms controlling the disease impact of larger genomic alterations.
Reference Key
hertzberg2022tadaagenome Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hertzberg, Jakob;Mundlos, Stefan;Vingron, Martin;Gallone, Giuseppe;
Journal Genome biology
Year 2022
DOI
67
URL
Keywords
Machine learning functional annotation copy-number-variants pathogenicity prediction structural variants tads

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.